Ipamorelin vs CJC-1295: two different receptors, two different half-lives, two different depths of human data. A research comparison of the ghrelin-receptor agonist and the long-acting GHRH analog.
Ipamorelin and CJC-1295 are routinely mentioned in the same breath, which obscures the fact that they are not variations on a theme. They act on two different receptors, on two different timescales, with two very different depths of published human data. Understanding that split is the whole comparison.
Growth hormone release from the anterior pituitary is governed by three inputs: growth-hormone-releasing hormone (GHRH), which stimulates via the GHRH receptor; somatostatin, which restrains; and ghrelin, which stimulates via the growth-hormone secretagogue receptor (GHS-R1a). CJC-1295 is a GHRH analog — it works on the first arm. Ipamorelin is a ghrelin-receptor agonist — it works on the third. Neither is a "better version" of the other, because they are not addressing the same node.
Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) first characterized by Raun and colleagues in 1998 and described at the time as the first selective growth-hormone secretagogue. The selectivity claim is the interesting part: earlier GHRPs released GH but also nudged ACTH, cortisol, and prolactin. Ipamorelin was reported to release GH without meaningfully moving those axes at the doses studied.
Its human pharmacokinetics were modelled by Gobburu and colleagues in 1999 in healthy male volunteers: dose-proportional exposure, a terminal half-life of roughly 2 hours, clearance around 0.078 L/h/kg, and a steady-state volume of distribution near 0.22 L/kg. Short-acting, in other words — consistent with a pulsatile release pattern rather than a sustained elevation.
Clinically, ipamorelin was developed by Novo Nordisk, later licensed onward, and taken into phase 2 work in postoperative ileus on the strength of its prokinetic (gut-motility) effects rather than its GH effects. That program did not advance. That is the honest ceiling of the dataset: PK/PD studies in volunteers plus a discontinued GI indication — no approved indication, no long-duration outcome trial.
CJC-1295 is a modified GHRH(1-29) fragment carrying a drug-affinity-complex (DAC) linker that binds covalently to circulating albumin. Albumin binding is the entire design premise — it converts a peptide whose native counterpart is cleared in minutes into one that persists for days.
The pivotal human data is Teichman and colleagues (2006, Journal of Clinical Endocrinology & Metabolism): two randomized, double-blind, placebo-controlled ascending-dose trials in healthy adults. A single subcutaneous injection produced dose-dependent increases in mean GH of roughly 2- to 10-fold sustained for six days or more, and increases in mean IGF-I of roughly 1.5- to 3-fold for nine to eleven days. With repeated dosing, IGF-I remained above baseline for up to 28 days. The estimated half-life was 5.8–8.1 days. Tolerability was reported as acceptable, particularly at 30 and 60 µg/kg.
A persistent source of confusion: "CJC-1295 without DAC" is not the same molecule. That label refers to modified GRF(1-29) — the same peptide backbone without the albumin-binding linker — and it behaves on a timescale of minutes, not days. The Teichman half-life figures apply only to the DAC version. We cover that distinction in more detail in CJC-1295 — with DAC or without?.
| Ipamorelin | CJC-1295 (with DAC) | |
|---|---|---|
| Class | Ghrelin-receptor (GHS-R1a) agonist / GHRP | GHRH analog |
| Structure | Pentapeptide, Aib-His-D-2-Nal-D-Phe-Lys-NH2 | Modified GHRH(1-29) + albumin-binding DAC linker |
| Human half-life | ~2 hours (Gobburu 1999) | 5.8–8.1 days (Teichman 2006) |
| Release pattern | Short, pulse-like GH release | Sustained GH and IGF-I elevation across days |
| Selectivity | Reported GH release without meaningful ACTH/cortisol/prolactin rise | Acts through the physiological GHRH receptor; still subject to somatostatin restraint |
| Human data depth | PK/PD volunteer studies; discontinued phase 2 in postoperative ileus | Randomized placebo-controlled phase 1 ascending-dose trials in healthy adults |
| Typical research framing | Pulsatility, short-window GH kinetics | Sustained IGF-I exposure, long dosing intervals |
The pairing is not arbitrary. GHRH and GHRP-class compounds have been reported to act synergistically on GH release since Bowers and colleagues described the effect in normal men in 1990 — the combined response exceeds the sum of the individual responses, and the mechanism is still not fully resolved. Later work on the determinants of that synergy (Veldhuis and colleagues, 2009) reinforced that the two inputs are not redundant.
That is the rationale behind combination preparations such as CJC-1295 + Ipamorelin. Whether it translates into any specific downstream outcome is a separate question the published literature does not answer.
Frame it as a design question, not a ranking:
One asymmetry worth stating plainly: CJC-1295 with DAC has randomized, placebo-controlled human data on its primary endocrine endpoints. Ipamorelin does not have an equivalent trial. That does not make ipamorelin ineffective — it makes the evidence base thinner. For broader context, see growth-hormone secretagogues — the category guide.
Elevated GH and IGF-I are biomarkers, not outcomes. The published human work on both compounds measured hormone concentrations and short-term tolerability. It did not establish effects on body composition, injury recovery, sleep architecture, athletic performance, or longevity, and it did not run long enough to characterize the safety of chronic IGF-I elevation.
Is CJC-1295 stronger than ipamorelin? They are not measured on a common scale. CJC-1295 with DAC produces a larger and far longer sustained elevation in GH and IGF-I in the published human trials, but it does so through a different receptor and over a different timescale. Ipamorelin's reported profile is a short, selective pulse.
Why are they so often combined? Because GHRH and GHRP-class compounds act on separate receptors and have been reported to release GH synergistically in humans since 1990. The combination is a mechanistic rationale, not evidence of a specific outcome.
What is the difference between CJC-1295 with and without DAC? The DAC linker binds albumin and extends the half-life to roughly 5.8–8.1 days. Without it, the peptide is modified GRF(1-29) and clears on a timescale of minutes. Published long-duration data applies only to the DAC version.
Does ipamorelin raise cortisol? The original characterization reported GH release without meaningful elevation of ACTH, cortisol, or prolactin at the doses tested — that selectivity is what distinguished it from earlier GHRPs. It has not been characterized across a wide dose range in large human studies.
Which has better human evidence? CJC-1295 with DAC, on endocrine endpoints specifically. Its phase 1 program was randomized, double-blind, and placebo-controlled. Ipamorelin's human record consists of volunteer PK/PD work and a discontinued phase 2 in postoperative ileus.